GlassScriptPhysician profile
Lee S Halpern
NPI 1629070164
$3,425.52
in general payments reported to CMS, 2019-2025
27 companies · $416 in 2025
The $416 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $1,229 · 2021: $434 · 2022: $278 · 2023: $482 · 2024: $255 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $937.50 | 2020 | |
| Abbvie INC. | $724.67 | 2019-2024 | |
| Astellas Pharma US INC | $231.87 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $214.70 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $165.66 | 2021-2025 | |
| Sage Therapeutics, LLC | $137.47 | 2023-2025 | Zurzuvae |
| Allergan, INC. | $130.26 | 2019-2022 | |
| Coopersurgical, INC. | $119.94 | 2020-2025 | Paragard T 380a, Paragard T 380a, Sos |
| Exeltis, USA INC. | $109.93 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $71.69 | 2023-2025 | Myfembree |
| Millicent US INC | $66.15 | 2019-2025 | Intrarosa, Femlyv |
| Evofem Biosciences, INC. | $65.39 | 2023-2024 | Phexxi |
| Organon LLC | $53.77 | 2023 | Nexplanon |
| Aspira Women'S Health INC | $51.00 | 2022-2023 | Ova1 |
| Supernus Pharmaceuticals, INC. | $49.10 | 2025 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.19 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $37.81 | 2021 | |
| Hologic Sales and Service, LLC | $33.49 | 2019-2021 | |
| Covidien LP | $32.25 | 2019 | |
| Mallinckrodt Enterprises LLC | $26.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.89 | 2019 | |
| Urovant Sciences INC | $21.96 | 2022 | |
| Agile Therapeutics, INC. | $20.61 | 2021 | |
| Myovant Sciences INC. | $17.49 | 2021 | |
| Meditrina | $15.12 | 2021 | |
| Pfizer INC. | $13.87 | 2023 | |
| Amag Pharmaceuticals, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.